Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
HYB 039-06-02 has specificity for human properdin.
HYB 039-06-02 has been successfully used in ELISA and Western blotting procedures. HYB 039-06-02 reacts strongly with properdin isolated from human plasma when tested in sandwich ELISA using a polyclonal antibody against properdin, only very low reaction is seen with plasma from patients deficient in properdin. HYB 039-06-02 works equally well in ELISA with purified properdin coated directly onto the microtiter well. In Western blotting after SDS-PAGE HYB 039-06-02 reacts with properdin in both reduced (subunits of 25 kDa and 56 kDa) as well as unreduced forms (220 kDa). After coupling to an activated CNBr-sepharose column, HYB 039-06-02 is suitable for affinity purification of human properdin.
The HYB 039-06-02 immunogen is Properdin isolated from human plasma.
Epitope specificity differs from that of HYB 039-04-02 but slightly overlap as determined by inhibition ELISA.
NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/ml
This gene encodes a plasma glycoprotein that positively regulates the alternative complement pathway of the innate immune system. This protein binds to many microbial surfaces and apoptotic cells and stabilizes the C3- and C5-convertase enzyme complexes in a feedback loop that ultimately leads to formation of the membrane attack complex and lysis of the target cell. Mutations in this gene result in two forms of properdin deficiency, which results in high susceptibility to meningococcal infections.
仅用于科研。不用于诊断过程。未经明确授权不得转售。